Risk and Volatility
Avenue Therapeutics has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
Valuation & Earnings
This table compares Avenue Therapeutics and NexImmune”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | $0.76 | 0.84 |
| NexImmune | N/A | N/A | -$32.34 million | ($18.29) | 0.00 |
Insider & Institutional Ownership
17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 14.9% of NexImmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Avenue Therapeutics and NexImmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
| NexImmune | N/A | -534.32% | -213.72% |
Summary
Avenue Therapeutics beats NexImmune on 5 of the 8 factors compared between the two stocks.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
About NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
